Ruscogenin suppresses mouse neutrophil activation: Involvement of protein kinase A pathway. Issue 154 (November 2015)

• Record Type: Journal Article
• Authors: Lin, Y.N.; Jia, R.; Liu, Y.H.; Gao, Y.; Wang, L.L.; Kou, J.P.; Yu, B.Y.
• Is Part Of: Journal of steroid biochemistry and molecular biology. Issue 154(2015)
• Page Start: 85
• Page End: 93
• Publication Date: 2015-11
• Subjects: Ruscogenin -- Neutrophils -- Superoxide anion -- NADPH oxidase -- Signaling pathways; Steroid hormones -- Periodicals; Biochemistry -- Periodicals; Hormones -- Periodicals; Molecular Biology -- Periodicals; Hormones stéroïdes -- Périodiques; Steroid hormones; Periodicals; 572.579
• DOI: 10.1016/j.jsbmb.2015.06.003
• Languages: English
• ISSNs: 0960-0760

Abstract

Highlights: Ruscogenin inhibited FMLP- and PMA-induced superoxide generation in neutrophils. Ruscogenin inhibited mouse neutrophil activation via multiple pathways. PKA was involved in the suppression of neutrophil activation by ruscogenin. Abstract: Ruscogenin, a natural steroidal sapogenin, presents in both food and medicinal plants. It has been found to exert significant anti-inflammatory activities. Considering that activation of neutrophil is a key feature of inflammatory diseases, this study was performed to investigate the inhibitory effect of ruscogenin and its underlying mechanisms responsible for neutrophil activation. Ruscogenin displayed potent antioxidative effects against Formyl-Met-Leu-Phe (FMLP)-induced extra- and intracellular superoxide generation in mouse bone marrow neutrophils, with IC50 values of 1.07 ± 0.32 μM and 1.77 ± 0.46 μM, respectively. Phorbol myristate acetate (PMA)-elicited extra- and intracellular superoxide generation were also suppressed by ruscogenin, with IC50 values of 1.56 ± 0.46 μM and 1.29 ± 0.49 μM, respectively. However, ruscogenin showed weak inhibition in NaF-induced response. Inhibition of superoxide generation was mediated neither by a superoxide-scavenging ability nor by a cytotoxic effect. Furthermore, ruscogenin inhibited the membrane translocation of p47phox and p67phox. It reduced FMLP-induced phosphorylation of cytosolic phospholipase A2 (cPLA2 ) and p21-activated kinase (PAK). The cellular cyclic adenosine monophosphate (cAMP) levels and protein kinase A (PKA) expression were increased by ruscogenin. Moreover, ruscogenin inhibited phosphorylation of protein kinase B (Akt), p38 mitogen-activated protein kinase (p38MAPK), extracellular signal-regulated kinase 1 and 2 (ERK1/2), and c-Jun N-terminal kinase (JNK). In addition, the inhibitory effects of ruscogenin on superoxide production and the phosphorylation of Akt, p38MAPK, and ERK1/2 were reversed by PKA inhibitor (H89), suggesting a PKA-dependent mechanism. In summary, our data suggest that ruscogenin inhibits activation of neutrophil through cPLA2, PAK, Akt, MAPKs, cAMP, and PKA signaling pathways. Increased PKA activity is associated with suppression of the phosphorylation of Akt, p38MAPK, and ERK1/2 pathways.